Elevance Health previews lower third-quarter earnings for Elevance Health stock

Published on 10/01/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elevance Health stock faces USD 4.72 adjusted earnings per share in the third quarter. Market value was USD 84.3 billion on September 30, 2026.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health (ISIN US2855211023) is preparing for a weaker third-quarter earnings comparison, with adjusted earnings per share forecast at USD 4.72, down 21.70 percent from USD 6.03 a year earlier. Yahoo Finance published the forecast on September 30, 2026, ahead of the company's scheduled third-quarter report on October 21, 2026.

Forecast points to a tougher quarter

The projected USD 4.72 adjusted earnings per share compares with USD 6.03 in the third quarter of 2025, while the forecast for fiscal 2026 stands at USD 27.19, down 10.20 percent from USD 30.29 in fiscal 2025. The figures frame the next report around earnings pressure rather than revenue expansion.

Elevance Health entered the comparison with second-quarter operating revenue of USD 49.80 billion, up 0.80 percent year over year, and adjusted diluted earnings per share of USD 7.45. Fortune reported that the second-quarter result exceeded management's outlook on July 15, 2026.

Guidance provides a higher baseline

Management raised full-year 2026 adjusted diluted earnings per share guidance to at least USD 27 and lifted operating cash flow guidance to at least USD 6 billion. The company also said it remained confident in returning to at least 12.00 percent adjusted earnings per share growth in 2027, according to Fortune.

The operating backdrop is mixed inside the portfolio. Second-quarter medical membership ended at 44.9 million, operating cash flow reached USD 1.9 billion, and the company described Medicaid as a business with elevated utilization and a full-year operating margin outlook of negative 1.75 percent.

Market value and reporting date

Elevance Health had a market capitalization of USD 84.3 billion as of September 30, 2026. Its 52-week range was USD 274.84 to USD 436.24, placing the latest structured market snapshot below the yearly high by USD 47.42, while the next earnings date is October 21, 2026.

The combination of a lower adjusted earnings forecast and higher full-year guidance creates a narrow test for the upcoming report: second-half execution must offset the year-over-year comparison pressure while Medicaid costs remain elevated. The scheduled report on October 21, 2026, is therefore the next dated company event for Elevance Health stock.